24 completed, 2 terminated, 1 recruiting, 1 unknown. 8 Phase 2, 8 Phase 4, 5 Phase 3, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 2 |
| Phase 4 | 8 | Completed 5, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 5 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow this drug Literature Review of Amphetamine trials Research Report on Amphetamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD). Dyanavel XR, Placebo - Fatigue, Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Rochester Center for Behavioral Medicine | 50 | 2024-09-01 | 2024-11-21 |
| FASST - Fetal Alcohol Spectrum Stimulant Trial Methylphenidate Hydrochloride, Placebo, Methylphenidate hydrochloride - Fetal Alcohol Spectrum Disorders | Phase 4 | Unknown | Monash Medical Centre | 20 | 2022-02-14 | 2022-12-13 |
| The Day-time Response Variation of (Lis)Dexamphetamine Dexamfetamine Sulfate 5 Mg Oral Tablet, Lisdexamfetamine Dimesylate, blood samples - Adhd | Completed | Amsterdam UMC, location VUmc | 16 | 2021-07-01 | 2023-05-10 | |
| Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate - Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder | Completed | Nemours Children's Clinic | 70 | 2020-09-13 | 2022-12-13 | |
| 8 Week Multi-site Study of MYDAYIS® for Bipolar Depression Mydayis Extended-Release Capsule, Placebo - Bipolar Depression | Phase 2 | Completed | Mayo Clinic | 74 | 2020-07-17 | 2025-08-12 |
| A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine Methylphenidate, Lisdexamfetamine, Atomoxetine - Attention Deficit Disorder With Hyperactivity | Completed | Janssen Research & Development, LLC | 430000 | 2019-10-09 | 2025-06-25 | |
| ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder ADZENYS XR-ODT, Placebo Oral Tablet - Attention Deficit Hyperactivity Disorder | Phase 4 | Withdrawn | Aytu BioPharma, Inc. | 2019-05-01 | 2025-10-03 | |
| Impact of Combined Medication and Behavioral Treatment for ASD & ADHD Amphetamine, ESDM informed parent coaching, Placebo Oral Tablet - Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder | Phase 2 | Terminated | Duke University | 18 | 2018-12-14 | 2022-03-22 |
| Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate Amphetamine Sulfate, Placebo - Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Arbor Pharmaceuticals, Inc. | 320 | 2018-09-18 | 2024-09-03 |
| Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years Amphetamine Extended Release Suspension [Dyanavel] - Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | Tris Pharma, Inc. | 5 | 2018-05-07 | 2019-06-25 |
| Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension - Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Tris Pharma, Inc. | 18 | 2017-02-11 | 2019-07-22 |
| Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing LSD, MDMA, Amphetamine - Healthy | Early Phase 1 | Completed | University Hospital, Basel, Switzerland | 28 | 2017-02-01 | 2018-10-15 |
| A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS) Amphetamine, TAK -041, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) - Healthy Volunteers | Phase 1 | Completed | Neurocrine Biosciences | 12 | 2016-12-05 | 2021-03-19 |
| Omega-3 Supplementation to ADHD Medication in Children Omega-3 Fatty Acid, ADHD Medication - Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation | Phase 4 | Completed | Massachusetts General Hospital | 21 | 2014-07-01 | 2017-06-29 |
| Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting AR11, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Completed | Arbor Pharmaceuticals, Inc. | 97 | 2013-12-01 | 2020-07-21 |
| Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers Amphetamine - Nicotine Dependence | Completed | Yale University | 49 | 2012-12-01 | 2023-03-02 | |
| Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD d-Amphetamine Transdermal Patch, Placebo patch - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Noven Pharmaceuticals, Inc. | 110 | 2012-10-01 | 2023-12-21 |
| Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm Amphetamine - Nicotine Dependence, Healthy | Not applicable | Completed | Yale University | 10 | 2012-06-01 | 2020-03-06 |
| Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits ADHD Medication, Omega-3 Fatty Acids - Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR) | Phase 2 | Completed | Massachusetts General Hospital | 2 | 2012-02-01 | 2018-10-23 |
| Monoamine Contributions to Neurocircuitry in Eating Disorders [11C]raclopride, [11C]DASB, amphetamine - Eating Disorder | Phase 4 | Completed | University of California, San Diego | 88 | 2011-05-01 | 2020-04-27 |
Showing 20 of 29. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (20) · Cocaine-Related Disorders (2) · Substance-Related Disorders (2) · Tobacco Use Disorder (2) · Autism Spectrum Disorder (1) · Bipolar Disorder (1) · Chronic Pain (1) · Fatigue (1) · Feeding and Eating Disorders (1) · Fetal Alcohol Spectrum Disorders (1) · Impulsive Behavior (1) · Spasm (1) · Stroke (1)
Shire (5) · Arbor Pharmaceuticals, Inc. (2) · Massachusetts General Hospital (2) · Tris Pharma, Inc. (2) · Yale University (2) · Amsterdam UMC, location VUmc (1) · Aytu BioPharma, Inc. (1) · Duke University (1) · Emory University (1) · Janssen Research & Development, LLC (1) · Mayo Clinic (1) · Monash Medical Centre (1) · Nemours Children's Clinic (1) · Neurocrine Biosciences (1) · Noven Pharmaceuticals, Inc. (1)
United States (20) · Australia (1) · Netherlands (1) · Switzerland (1) · United Kingdom (1)
Alison Crichton, PhD (1) · Ann Childress, MD (1) · Antonio Pardo, MD (1) · Barth L Wilsey, MD (1) · Carolyn R Sikes, PhD (1) · Cathrin M Buetefisch, MD (1) · Craig Surman, MD (1) · David V Herin, Ph.D (1) · Frederick G Moeller, MD (1) · Geraldine Dawson, PhD (1) · James Waxmonsky, MD (1) · Joel Young, MD (1) · Kelly Cosgrove, Ph.D. (1)
PMID 20861587, PMID 19012813, PMID 19026251, PMID 19660492, PMID 19877974, PMID 21824454, PMID 25414797, PMID 29087231, PMID 30575407, PMID 30972657, PMID 31228031, PMID 34428356, PMID 35020462, PMID 36913518, PMID 37339441, PMID 38631835
P50DA009262 (2), 2016 (1), K02DA031750 (1), P50CA196530 (1), P50HD093074 (1), R01MH092793 (1), R01NS060830 (1), R25MH071584 (1)